Francis Brown
Harvard University
5 Papers
46 Citations
Francis Brown is an academic researcher from Harvard University. The author has contributed to research in topics: Internal medicine & Decitabine. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)*
Amy E. DeZern,Amer M. Zeidan,John Barnard,Wesley Hand,Najla Al Ali,Francis Brown,Cassie Zimmerman,Gail J. Roboz,Guillermo Garcia-Manero,David P. Steensma,Rami S. Komrokji,Mikkael A. Sekeres +11 more
TL;DR: First-line therapy for higher-risk myelodysplastic syndromes (MDS) includes decitabine (DAC) or azacitidine (AZA) but Variables have not identified differential response rates between these, and the influence of patient sex on outcomes including overall survival is assessed.
Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML)
Richard Stone,Daniel J. DeAngelo,Anthony Letai,Jeremy M. Stewart,Michael McGinnis,Francis Brown,Geoffrey Fell,Yael Flammand,Marina Konopleva,Jacqueline S. Garcia,Marlise R. Luskin +10 more
TL;DR: It is hypothesized that VEN in combination with "3+7" could lead to a higher rate of measurable residual disease (MRD)-negative CR, perhaps obviating the need for reinduction as well as limiting relapse without undue toxicity.
13
Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)
Rami S. Komrokji,Amy E. DeZern,Katrina Zell,Najla Al Ali,Christopher Estling,Cassie Zimmerman,Wesley Hand,Francis Brown,Nicole Rizzo,John Barnard,Gail J. Roboz,Guillermo Garcia-Manero,David P. Steensma,Mikkael A. Sekeres +13 more
TL;DR: The best response by IWG 2006 criteria to first line therapy in higher-risk MDS correlates with OS, while pts who achieved SD or better response had improved outcome compared to PD, with mCR having an OS equivalent to SD.
10
Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC)
Rami S. Komrokji,Amy E. DeZern,Katrina Zell,Najla Al Ali,Eric Padron,Christopher Estling,Cassie Zimmerman,Wesley Hand,Francis Brown,Nicole Rizzo,John Barnard,Gail J. Roboz,Hetty E. Carraway,Jaroslaw P. Maciejewski,Alan F. List,Guillermo Garcia-Manero,David P. Steensma,Mikkael A. Sekeres +17 more
TL;DR: SF3B1 somatic mutation in MDS is commonly associated with RS, lower risk disease, and better OS, and biologically rational therapies are needed that target this molecular disease subset.
4
Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)
Amy E. DeZern,Amer M. Zeidan,John Barnard,Wesley Hand,Najla Al Ali,Francis Brown,Cassie Zimmerman,Gail J. Roboz,Rami S. Komrokji,Guillermo Garcia-Manero,David P. Steensma,Mikkael A. Sekeres +11 more
TL;DR: Women with higher-risk MDS may live longer when treated with DAC than with AZA, and future prospective investigations of both drugs in men and women are warranted.
3